文献速递心脑血管急症

流感疫苗接种与心血管风险的关联:一项荟萃分析

Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis.
PubMed 文献 · JAMA Netw Open · 2022-04-01
一句话结论流感疫苗接种与主要不良心血管事件风险降低34%相关,近期急性冠脉综合征患者风险降低45%。

该荟萃分析纳入6项随机对照试验共9001例患者(平均年龄65.5岁,42.5%女性,52.3%有心脏病史),评估季节性流感疫苗接种与致命和非致命心血管事件风险的关联。结果显示,流感疫苗与复合心血管事件风险降低相关(3.6% vs 5.4%;RR 0.66;95% CI 0.53-0.83;P < .001)。近期急性冠脉综合征患者(RR 0.55;95% CI 0.41-0.75)与无近期急性冠脉综合征患者(RR 1.00;95% CI 0.68-1.47)之间存在治疗交互作用(交互P = .02)。心血管死亡率方面也检测到治疗交互作用(近期ACS RR 0.44;95% CI 0.23-0.85 vs 无近期ACS RR 1.45;95% CI 0.84-2.50;交互P = .006),总心血管死亡为疫苗组1.7% vs 对照组2.5%(RR 0.74;95% CI 0.42-1.30;P = .29)。作者认为,鉴于COVID-19大流行期间流感对人群健康的威胁,向高危患者告知流感疫苗的心血管获益是必要的。

要点

  • 6项RCT共9001例患者,流感疫苗与复合心血管事件风险降低相关(3.6% vs 5.4%;RR 0.66;95% CI 0.53-0.83;P < .001)。
  • 近期急性冠脉综合征(1年内)患者接种流感疫苗与主要不良心血管事件风险降低45%相关(RR 0.55;95% CI 0.41-0.75)。
  • 无近期急性冠脉综合征患者中,流感疫苗与复合心血管事件风险无显著关联(RR 1.00;95% CI 0.68-1.47)。
  • 心血管死亡率存在治疗交互作用:近期ACS患者RR 0.44(95% CI 0.23-0.85),无近期ACS患者RR 1.45(95% CI 0.84-2.50)(交互P = .006)。
  • 总体心血管死亡疫苗组1.7% vs 对照组2.5%(RR 0.74;95% CI 0.42-1.30;P = .29),未达统计学显著。

适用人群与场景

  • 纳入2000年至2021年发表的随机对照试验,参与者为国际多中心RCT招募的住院和门诊患者,随机接受流感疫苗或安慰剂/对照。
  • 共6项RCT、9001例患者,平均年龄65.5岁,42.5%女性,52.3%有心脏病史。
  • 按随机化前1年内有无近期急性冠脉综合征进行分层分析。

研究设计与关键结果

  • 研究类型:更新的荟萃分析,纳入6项已发表RCT共9001例患者。
  • 主要终点:复合主要不良心血管事件,流感疫苗组3.6% vs 安慰剂/对照组5.4%(RR 0.66;95% CI 0.53-0.83;P < .001)。
  • 亚组交互:近期ACS患者RR 0.55(95% CI 0.41-0.75) vs 无近期ACS患者RR 1.00(95% CI 0.68-1.47),交互P = .02。
  • 心血管死亡:总体疫苗组1.7% vs 对照组2.5%(RR 0.74;95% CI 0.42-1.30;P = .29);近期ACS患者RR 0.44(95% CI 0.23-0.85) vs 无近期ACS患者RR 1.45(95% CI 0.84-2.50),交互P = .006。
  • 随访时间:12个月内。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与荟萃分析;采用PRISMA指南提取数据,Cochrane协作工具评估偏倚风险,Cochrane标准评价试验质量。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,鉴于COVID-19大流行期间流感对人群健康的威胁,向高危患者告知流感疫苗的心血管获益是必要的。
  • 作者认为,流感疫苗接种与主要不良心血管事件风险降低34%相关,近期ACS患者风险降低45%。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Influenza infection is associated with increased cardiovascular hospitalization and mortality. Our prior systematic review and meta-analysis hypothesized that influenza vaccination was associated with a lower risk of cardiovascular events.

OBJECTIVE: To evaluate, via an updated meta-analysis, if seasonal influenza vaccination is associated with a lower risk of fatal and nonfatal cardiovascular events and assess whether the newest cardiovascular outcome trial results are consistent with prior findings.

DATA SOURCES: A previously published meta-analysis of randomized controlled trials (RCTs) and a large 2021 cardiovascular outcome trial.

STUDY SELECTION: Studies with RCTs published between 2000 and 2021 that randomized participants to either influenza vaccine or placebo/control. Eligible participants were inpatients and outpatients recruited for international multicenter RCTs and randomized to receive either influenza vaccine or placebo/control.

DATA EXTRACTION AND SYNTHESIS: PRISMA guidelines were followed in the extraction of study details, and risk of bias was assessed using the Cochrane Collaboration tool. Trial quality was evaluated using Cochrane criteria. Data were analyzed January 2020 and December 2021.

MAIN OUTCOMES AND MEASURES: Random-effects Mantel-Haenszel risk ratios (RRs) and 95% CIs were derived for a composite of major adverse cardiovascular events and cardiovascular mortality within 12 months of follow-up. Where available, analyses were stratified by patients with and without recent acute coronary syndrome (ACS) within 1 year of randomization.

RESULTS: Six published RCTs comprising a total of 9001 patients were included (mean age, 65.5 years; 42.5% women; 52.3% with a cardiac history). Overall, influenza vaccine was associated with a lower risk of composite cardiovascular events (3.6% vs 5.4%; RR, 0.66; 95% CI, 0.53-0.83; P < .001). A treatment interaction was detected between patients with recent ACS (RR, 0.55; 95% CI, 0.41-0.75) and without recent ACS (RR, 1.00; 95% CI, 0.68-1.47) (P for interaction = .02). For cardiovascular mortality, a treatment interaction was also detected between patients with recent ACS (RR, 0.44; 95% CI, 0.23-0.85) and without recent ACS (RR, 1.45; 95% CI, 0.84-2.50) (P for interaction = .006), while 1.7% of vaccine recipients died of cardiovascular causes compared with 2.5% of placebo or control recipients (RR, 0.74; 95% CI, 0.42-1.30; P = .29).

CONCLUSIONS AND RELEVANCE: In this study, receipt of influenza vaccination was associated with a 34% lower risk of major adverse cardiovascular events, and individuals with recent ACS had a 45% lower risk. Given influenza poses a threat to population health during the COVID-19 pandemic, it is integral to counsel high-risk patients on the cardiovascular benefits of influenza vaccination.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Behrouzi B, Bhatt DL, Cannon CP, et al. Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis. JAMA Netw Open. 2022. PMID: 35486404. doi:10.1001/jamanetworkopen.2022.8873

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。